185 related articles for article (PubMed ID: 35302600)
1. Aberrant Activation of Cell-Cycle-Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma.
Yoshida K; Yokoi A; Yamamoto T; Hayashi Y; Nakayama J; Yokoi T; Yoshida H; Kato T; Kajiyama H; Yamamoto Y
Clin Cancer Res; 2022 May; 28(10):2147-2159. PubMed ID: 35302600
[TBL] [Abstract][Full Text] [Related]
2. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
3. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.
Lützen U; Zhao Y; Lucht K; Zuhayra M; Marx M; Cascorbi I; Culman J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):37-48. PubMed ID: 27664035
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma.
Kang CW; Hannan KM; Blackburn AC; Loh AHP; Hong KC; Yuan GJ; Hein N; Drygin D; Hannan RD; Coupland LA
Invest New Drugs; 2022 Jun; 40(3):529-536. PubMed ID: 35201535
[TBL] [Abstract][Full Text] [Related]
6. Curcumin induces cross-regulation between autophagy and apoptosis in uterine leiomyosarcoma cells.
Li B; Takeda T; Tsuiji K; Wong TF; Tadakawa M; Kondo A; Nagase S; Yaegashi N
Int J Gynecol Cancer; 2013 Jun; 23(5):803-8. PubMed ID: 23532091
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Paula Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG
Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645
[TBL] [Abstract][Full Text] [Related]
8. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
11. The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line.
Chuang TD; Ho M; Khorram O
Reprod Sci; 2015 May; 22(5):563-71. PubMed ID: 25305131
[TBL] [Abstract][Full Text] [Related]
12. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
[TBL] [Abstract][Full Text] [Related]
13. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.
Eskander RN; Randall LM; Sakai T; Guo Y; Hoang B; Zi X
J Obstet Gynaecol Res; 2012 Aug; 38(8):1086-94. PubMed ID: 22540374
[TBL] [Abstract][Full Text] [Related]
14. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Knipstein J; Dubuc A; Taylor MD; Handler MH; Foreman NK; Vibhakar R
BMC Cancer; 2012 Mar; 12():80. PubMed ID: 22390279
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
19. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
[TBL] [Abstract][Full Text] [Related]
20. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
[Next] [New Search]